Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
StockNews.AI · 3 hours
AI Summary
Crinetics reports positive Phase 2 CAH data for atumelnant, showing a 67% A4 reduction at 12 weeks and 88% of participants reaching physiologic glucocorticoid dosing. ADCS data show rapid cortisol and UFC declines, with most adverse events mild and manageable with GC replacement. The results bolster CALM-CAH Phase 3 progression and may trigger near-term value catalysts for CRNX.
Sentiment Rationale
Strong biomarker signals (A4, 11-OHA4, 11-KT) and physiologic GC dose attainment in CAH, plus rapid cortisol/UFC reductions in ADCS, improve the probability of a successful Phase 3 readout and potential market expansion; however, small sample sizes and lack of long-term safety data keep gains modest until confirmed in larger trials.
Trading Thesis
Bullish on CRNX near-term as CAH data de-risks progress toward CALM-CAH Phase 3; accumulate on pullbacks.
Market-Moving
- Endo 2026 data presentations highlight Atumelnant efficacy signals.
- CALM-CAH Phase 3 trial timeline remains a key catalyst.
- Small open-label cohorts and sample sizes temper conviction.
Key Facts
- Phase 2 CAH Cohort 4: A4 down 67% at week 12; 88% reached physiologic GC dose.
- 11-OHA4 down 64% and 11-KT down 56% by week 12; morning dosing effective.
- ADCS Phase 1b/2a: cortisol and UFC fall rapidly; 3/6 UFC at ULN by day 10.
- 40 mg cohort data and ENDO 2026 presentations bolster CALM-CAH Phase 3 prospects.
- Crinetics plans Phase 3 CALM-CAH and pediatric trials; potential long-run upside.
Companies Mentioned
- Crinetics Pharmaceuticals, Inc. (CRNX): Phase 2 CAH data show strong biomarker reductions; CALM-CAH Phase 3 advancement potential.
- Endocrine Society (N/A): Endo 2026 presentation of atumelnant data; not an investible entity.
- National Institutes of Health (N/A): Collaborative Phase 1b/2a Cushing's trial; potential for expanded studies.
- University College London Hospitals NHS Foundation Trust (N/A): Clinical investigator on atumelnant study; no direct market impact.
Industry News
Industry News. The report highlights meaningful biomarker improvements and GC-dose reductions for atumelnant, supporting a path toward Phase 3. While promising, the data stem from small open-label cohorts, so investors should weigh durability and regulatory timelines before pricing in a major revaluation.